Nammi Therapeutics, Inc. is an immunotherapy company developing first in class products for the treatment of cancer. Seeking to extend the benefits of immunotherapy to all cancer patients, Nammi has identified three key principles that have limited immunotherapies to date:
The redundancy of immune regulatory pathways requires synergistic combinations for robust and broad efficacy.
Potent immune stimulators must be dampened in circulation to avoid systemic toxicities.
Optimal therapies must employ mechanisms to selectively deliver and activate them within tumors to focus activated immune cells on killing the tumor rather than the healthy tissue.